Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Multi-Center Safety and Efficacy Study of Co-Administration of Tesofensine/Metoprolol for 12 Weeks in Adult and Adolescent Patients With Prader-Willi Syndrome (PWS), Followed by Two Open Label 12 Weeks Extension Periods for Adolescent Patients

NCT03149445 is registered in ClinicalTrials.gov with Saniona as lead sponsor.

NCT NCT03149445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03149445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Multi-Center Safety and Efficacy Study of Co-Administration of Tesofensine/Metoprolol for 12 Weeks in Adult and Adolescent Patients With Prader-Willi Syndrome (PWS), Followed by Two Open Label 12 Weeks Extension Periods for Adolescent Patients
Lead sponsor
Saniona
Phase
Phase 2
Overall status
Completed
Start date
March 30, 2017
Completion date
July 22, 2019
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

confirmed genetic diagnosis of prader-willi syndrome